Neutralizing antibodies respond to a bivalent dengue DNA vaccine or/and a recombinant bivalent antigen

Molecular Medicine Reports

Volumn 11, Issue 2, 2015, Pages 1009-1016

  Zhang, Zhi Shan ^a   Weng, Yu Wei ^b   Huang, Hai Long ^b   Zhang, Jian Ming ^b   Yan, Yan Sheng ^b  

^a FUJIAN MEDICAL UNIVERSITY   (China)

^b Fujian Center for Disease Control and Prevention   (China)

Author keywords

Dengue vaccine; Dengue virus; Domain III; Envelope protein; Immunogenicity

Indexed keywords

DENGUE VIRUS; ESCHERICHIA COLI; EUKARYOTA; MUS; PROKARYOTA;

DNA VACCINE; NEUTRALIZING ANTIBODY; RECOMBINANT PROTEIN; VIRUS ANTIBODY; VIRUS VACCINE;

ANIMAL; BAGG ALBINO MOUSE; DENGUE; DENGUE VIRUS; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; IMMUNIZATION; IMMUNOLOGY; METABOLISM; MOUSE; PLASMID; SERODIAGNOSIS;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DENGUE; DENGUE VIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; IMMUNIZATION; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; PLASMIDS; RECOMBINANT PROTEINS; VACCINES, DNA; VIRAL VACCINES;

EID: 84916240584     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2850     Document Type: Article

References (44)

1. Agarwal R, Kapoor S, Nagar R, et al: A clinical study of the patients with dengue hemorrhagic fever during the epidemic of 1996 at Lucknow, India. Southeast Asian J Trop Med Public Health 30: 735-740, 1999.
2. Rosen L: Comments on the epidemiology, pathogenesis and control of dengue. Med Trop (Mars) 59: 495-498, 1999.
3. Morens DM and Halstead SB: Measurement of antibody-dependent infection enhancement of four dengue virus serotypes by monoclonal and polyclonal antibodies. J Gen Virol 71: 2909-2914, 1990.
4. Anderson R, Wang S, Osiowy C and Issekutz AC: Activation of endothelial cells via antibody-enhanced dengue virus infection of peripheral blood monocytes. J Virol 71: 4226-4232, 1997.
5. Bhamarapravati N and Sutee Y: Live attenuated tetravalent dengue vaccine. Vaccine 18 (Suppl 2): 44-47, 2000.
6. Eckles KH, Dubios DR, Putnak R, et al: Modification of dengue virus strains by passage in primary dog kidney cells: preparation of candidate vaccines and immunization of monkeys. Am J Trop Med Hyg 69 (Suppl): 12-16, 2003.
7. Putnak R, Barvir DA, Burrous JM, et al: Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys. J Infect Dis 174: 1176-1184, 1996.
8. Guirakhoo F, Pugachev K, Zhang Z, et al: Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J Virol 78: 4761-4775, 2004.
9. Van der Most RG, Murali-Krishna K, Ahmed R and Strauss JH: Chimeric yellow fever/dengue virus as a candidate dengue vaccine: Quantitation of the dengue virus-specific CD8 T-cell response. J Virol 74: 8094-8101, 2000.
10. Guirakhoo F, Arroyol J, Pugachev KV, et al: Construction, safety, and immunogenecity in nonhuman primates of a chimeric yellow fever dengue virus tetravalent vaccine. J Virol 75: 7290-7304, 2001.
11. Simmons M, Murphy GS, Kochel T, et al: Characterization of antibody responses to combinations of a dengue-2 DNA and dengue-2 recombinant subunit vaccine. Am J Trop Med Hyg 65: 420-426, 2001.
12. Mota J, Acosta M, Argotte R et al: Induction of protective antibodies against dengue virus by tetravalent DNA immunization of mice with domain III of the envelope protein. Vaccine 23: 3469-3476, 2005.
13. Wu SF, Liao CL, Lin YL, et al: Evaluation of protective efficacy and immune mechanisms of using a non-structural protein NS1 in DNA vaccine against dengue 2 virus in mice. Vaccine 21: 3919-3929, 2003.
14. Men R, Wyatt L, Tokimatsu I, et al: Immunization of rhesus monkeys with a recombinant of modified vaccina virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2 virus challenge. Vaccine 18: 3113-3122, 2000.
15. Simmons M, Nelson WM, Wu SJ and Hayes CG: Evaluation of the protective efficacy of a recombinant dengue envelope B domain fusion protein against dengue 2 virus infection in mice. Am J Trop Med Hyg 58: 655-662, 1998.
16. Simmons M, Murphy GS and Hayes CG: Short report: Antibody response of mice immunized with a tetravalent dengue recombinant protein subunit vaccine. Am J Trop Med Hyg 65: 159-161, 2001.
17. Hermida L, Rodriguez R, Lazo L, et al: A dengue-2 envelope fragment inserted within the structure of the P64k meningococcal protein carrier enables a functional immune response against the virus in mice. J Virol Methods 115: 41-49, 2004.
18. Kelly EP, Greene JJ, King AD and Innis BL: Purified dengue 2 virus envelope glycoprotein aggregates produced by baculovirus are immunogenic in mice. Vaccine 18: 2549-2559, 2000.
19. Chen Y, Maguire T and Marks RM: Demonstration of binding of dengue envelope protein to target cells. J Virol 70: 8765-8772, 1996.
20. Bray M and Lai CJ: Dengue virus premembrane and membrane proteins elicit a protective immune response. Virology 185: 505-508, 1991.
21. Rey FA, HeinA FX, Mandl C, et al: The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution. Nature 375: 291-298, 1995.
22. Roehrig JT, Volpe KE, Squires J, et al: Contribution of disulfide bridging to epitope expression of the dengue type 2 virus envelope glycoprotein. J Virol 78: 2648-2652, 2004.
23. Bhardwaj S, Holbrook M, Shope RE, et al: Biophysical characterization and vector-specific antagonist activity of domain III of the tick-borne flavivirus envelope protein. J Virol 75: 4002-4007, 2001.
24. Crill WD and Roehrig RT: Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus E glycoprotein are most efficient blockers of virus adsorption to Vero cells. J Virol 75: 7769-7773, 2001.
25. Megret F, Hugnot JP, Falconar MK, et al: Use of recombinant fusion proteins and monoclonal antibodies to define linear and discontinuous antigenic sites on the dengue envelope glycoprotein. Virology 187: 480-491, 1992.
26. Roehrig JT, Johnson AJ, Hunt AR, et al: Antibodies to dengue 2 virus E-glycoprotein synthetic peptides identity antigenic conformation. Virology 177: 668-675, 1990.
27. Hung JJ, Hsieh MT, Young MJ, et al: An external loop region of domain III of dengue virus type 2 envelope protein is involved in serotype-specific binding to mosquito but not mammalian cells. J Virol 78: 378-388, 2004.
28. Simmons M, Nelson WM, Wu SJ and Hayes CG: Evaluation of the protective efficacy of a recombinant dengue envelope B domain fusion protein against dengue 2 virus infection in mice. Am J Trop Med Hyg 58: 655-662, 1998.
29. Morens DM, Halstead SB, Repik PM, et al: Simplified plaque reduction assay for dengue viruses by semi-micromethods in BHK21 cells: comparison of the BHK suspension test standard plaque reduction neutralization. J Clin Microbio 22: 250-254, 1985.
30. Trirawatanapong T, Chandran B, Putnak R and Padmanabhan R: Mapping of a region of dengue virus type-2 glycoprotein required for binding by a neutralizing monoclonal antibody. Gene 116: 139-150, 1992.
31. Sun W, Edelman R, Kanesa-Thasan N, et al: Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. Am J Trop Med Hyg 69 (Suppl): 24-31, 2003.
32. Edelman R, Wasserman SS, Bodison SA, et al: Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am J Trop Med Hyg 69 (Suppl): 48-60, 2003.
33. Kitchener S, Nissen M, Nasveld P, et al: Immunogenicity and safety of two live-attenuated tetravalent dengue virus vaccine formulations in healthy Australian adults. Vaccine 24: 1238-1241, 2006.
34. Sabchareon A, Lang J, Chanthavanich P, et al: Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children. Pediatr Infect Dis J 23: 99-109, 2004.
35. Swaminathan S and Khanna N: Viral vaccines for dengue: the present and the future. WHO Dengue Bul 27: 181-191, 2003.
36. Kanesa-thasan N, Sun W, Kim-Ahn G, et al: Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine 19: 3179-3188, 2001.
37. Jaiswal S, Khanna N and Swaminathan S: High-level expression and one-step purification of recombinant dengue virus type 2 envelope domain III protein in Escherichia coli. Protein Expr Purif 33: 80-91, 2004.
38. Robinson CR and Sauer RT: Optimizing the stability of single-chain proteins by linker length and composition mutagenesis. Pro Natl Acad Sci USA 95: 5929-5934, 1998.
39. Putnak R, Feighny R, Burrous J, et al: Dengue-1 virus envelope glycoprotien gene expressed in recombinant baculovirus elicits virus-neutralizing antibody in mice and protects them from virus challenge. Am J Trop Med Hyg 45: 159-167, 1991.
40. Delenda C, Staropoli I, Frenkiel MP, et al: Analysis of C-terminally truncated dengue 2 and dengue 3 virus envelope glycoproteins: processing in insect cells and immunogenic properties in mice. J Gen Virol 75: 1569-1578, 1994.
41. Khanam S, Etemad B, Khanna N and Swaminathan S: Induction of neutralizing antibodies specific to dengue virus serotypes 2 and 4 by a bivalent antigen composed of linked envelope domains III of these two serotypes. Am J Trop Med Hyg 74: 266-277, 2006.
42. Chang GJ, Davis BS, Hunt AR, et al: Flavivirus DNA vaccines: current status and potential. Ann N Y Acad Sci 951: 272-285, 2001.
43. Sedegah M, Jones TR, Kaur M, et al: Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine. Proc Natl Acad Sci USA 95: 7648-7653, 1998.
44. Barnett SW, Rajasekar S, Legg H, et al: Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp 120 protein subunit. Vaccine 15: 869-873, 1997.